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Summary
 
The antiviral nature of tumor necrosis factor (TNF) is generally well accepted. TNF appears to
induce multiple antiviral mechanisms, and to synergize with interferon (IFN)-
 
g
 
 in promoting
antiviral activities. We infected TNF receptor (TNFR)-deficient mice with the virulent mu-
rine pathogen, ectromelia virus (EV), and observed that otherwise resistant mice were suscepti-
ble to lethal infection. To study the molecular basis of the antiviral action of TNF, mice were
infected with a recombinant vaccinia virus encoding murine TNF (VV-HA-TNF). In normal
mice, the replication of VV-HA-TNF was highly attenuated. In contrast, mice in which the
TNFR type 1 (p55) or the TNFR type 2 (p75) were genetically disrupted showed a moderate
defect in their capacity to clear the TNF-encoding virus. The contribution of both TNF re-
ceptors to the control of VV-HA-TNF was confirmed by the enhanced replication of VV-
HA-TNF in mice deficient for both p55 and p75. These observations were corroborated by
infecting TNFR-deficient mice with EV. For both infections, the p55 and p75 TNFRs were
necessary to maintain normal levels of resistance. Thus, the antiviral activity of TNF is medi-
ated via both TNFRs in vivo. Furthermore, these studies establish that TNF is an important
component of the host response to a natural virus infection.
 
M
 
any studies have demonstrated the antiviral potential
of TNF in vitro. Since recombinant TNF became
available 10 yr ago, it has been reported that TNF treat-
ment of some cell types reduced the infectivity of a number
of viruses (1–3) and synergized with IFN-
 
g
 
 to promote an-
tiviral function (1, 4).
Various studies of the effects of TNF on virus infection
have also illustrated antiviral activity in vivo. For instance,
the coexpression of TNF and viral proteins from a recom-
binant vaccinia virus (VV) lead to rapid attenuation of the
infection in mice (5). When mice were treated with TNF
before murine cytomegalovirus infection, the antiviral ef-
fects of IFN-
 
g
 
 were enhanced (6). However, the overall
picture obtained from anti-TNF treatment of virus-infected
mice is not clear and may reflect virus-specific differences
with respect to TNF sensitivity. In some cases, anti-TNF
treatment correlated with increased virus replication (7)
and reduced survival of murine cytomegalovirus–infected
mice (8). Other studies have reported no effects of anti-
TNF treatment on influenza virus (9) or lymphocytic
choriomeningitis virus (LCMV; 10) replication in mice,
although inflammation was reduced in some infections
(9, 11).
Perhaps the most compelling support for an antiviral role
for TNF comes from the demonstration that different virus
families encode factors which target TNF-dependent activ-
ities. Several of the poxviruses encode soluble versions of
TNF receptors (12–14) and importantly, disruption of the
viral TNFR gene in myxoma virus resulted in reduced vir-
ulence in vivo (13). Adenoviruses have been shown to en-
code multiple genes that can block the cytotoxic effects of
TNF (15). A further anti-TNF strategy appears to be en-
coded in the genomes of molluscum contagiosum virus and
equine herpesvirus type 2, both of which contain homo-
logues of death effector domains involved in p55-mediated
signaling (16). Overexpression of these viral genes inhibited
TNF-induced apoptosis. However, despite in vitro and in
vivo evidence of TNF-mediated antiviral activity, direct evi-
dence of a physiological role for TNF in the control of vi-
rus infection is rare.
The activities of TNF are mediated by binding to two
receptors: TNFR1, or p55, and TNFR2, or p75 (for re-
view see Aggarwal and Natarajan, reference 17). In line
with the majority of TNF-triggered events, most studies in
vitro suggested the dominance of p55 and no role for p75
in host antiviral activity (17, 18). However, no defect was
  
1592
 
Tumor Necrosis Factor (TNF)R1 and TNFR2 Mediate Antiviral Activity
 
observed in the antiviral responses of TNFR1-deficient mice
infected with VV or LCMV (19).
The studies described here aim to establish whether TNF
plays a determining role in the physiological control of a vi-
rus infection and to define the receptor specificity of the
antiviral activity of TNF.
 
Materials and Methods
 
Mice.
 
Mice bearing genetic mutations in TNFR1/p55 (20)
and TNFR2/p75 (21) have been previously described. Double
TNFR-deficient mice were generated by the appropriate inter-
crosses of p55 and p75 mutant mice (22, 23). All TNFR-deficient
mice used in these studies were hybrids between C57BL/6 and
129/Sv (B6 
 
3
 
 129). Control mice were (B6 
 
3
 
 129)F2. The deri-
vation of p75
 
2
 
/
 
2
 
 and p55
 
2
 
/
 
2
 
p75
 
2
 
/
 
2
 
 mice has been described else-
where (21–23). All mice were bred and housed under specific
pathogen-free conditions at the Animal Breeding Establishment,
John Curtin School of Medical Research (Canberra, Australia).
Genotypes of the mutant and wild-type mice were confirmed by
PCR. Mice used in these studies were between 6 and 12 wk of
age. Previous data show that both strains contribute to resistance
to ectromelia virus (EV) and that B6 
 
3
 
 129 are more resistant
than either parent (Ruby, J., unpublished results). Both B6 and
129 strains also contribute to resistance to VV and increased resis-
tance to VV is seen in B6 
 
3
 
 129.
 
Viruses.
 
The construction of the recombinant vaccinia vi-
ruses, VV-HA-TNF and VV-HA-TK (herpes simplex virus thy-
midine kinase gene), has been previously reported (5, 24). Both
viruses also encode the hemagglutinin (HA) gene from influenza
virus (A/PR-8). Stocks of rVV were prepared as crude stocks
from CV-1 cells. EV (Moscow strain) was prepared as a crude
stock from BSC-1 cells.
 
Infection of Mice and Assay of Virus Replication.
 
To study repli-
cation of VV-HA-TNF or VV-HA-TK, female mice were inoc-
ulated intravenously with 10
 
7
 
 PFU of rVV in 200 
 
m
 
l saline. After
3 d, mice were killed and ovaries were harvested for titration of
virus using a plaque assay on 143B cells (25). Mice treated with
soluble (s)TNFR received a fusion protein of human TNFR2/
p75 linked to the Fc portion of human IgG1 (26). Mice were in-
oculated intraperitoneally with 300 
 
m
 
g sTNFR on days 0, 1, and
2 after infection and with VV-HA-TNF on day 0. Mice were
killed and the ovaries collected on day 3. To investigate EV repli-
cation, male mice were infected in the right hind footpad with 5 
 
3
 
10
 
3
 
 PFU of EV in a volume of 20 
 
m
 
l using a 30 gauge needle.
Mice infected with EV were killed 7 d after infection and liver,
spleen, and inoculated foot (amputated at the first joint) were har-
vested. EV was titrated using BSC-1 cells (27). The limit of sensi-
tivity of the infectious plaque assay is 100 PFU. Values below the
level of plaque assay sensitivity were assigned a value of 50 PFU.
 
Results
 
Residual TNF-mediated Antiviral Activity in p55
 
2
 
/
 
2
 
 Mice.
 
It has been previously shown that overexpression of TNF
by an rVV caused an attenuated infection in mice (5). To
determine whether the enhanced clearance of rVV encod-
ing the gene for murine TNF (VV-HA-TNF) was depen-
dent on p55, mice deficient for this receptor were infected
with VV-HA-TNF. In three separate experiments, a small
but significant (
 
P
 
 
 
,
 
0.05) increase in VV-HA-TNF replica-
tion was measured in p55-mutant compared to wild-type
mice (Table 1). However, the increased replication of VV-
HA-TNF in p55
 
2
 
/
 
2
 
 mice represented only partial reversal
of attenuation since the yield of the control virus construct,
VV-HA-TK, in these mice was three orders of magnitude
higher (Table 1). The finding that VV-HA-TNF replication
was limited in p55
 
2
 
/
 
2
 
 mice was surprising given that p55
has been shown to mediate the antiviral activity of TNF in
vitro (18). Despite the lack of p55, TNF was able to acti-
vate antiviral mechanisms which resulted in the rapid reso-
lution of VV infection. The attenuation of VV in this
model was dependent on TNF since treatment of p55-
mutant mice with sTNFR resulted in significantly increased
replication of VV-HA-TNF (
 
P
 
 
 
,
 
0.05; Table 1). Thus, the
TNF-dependent inhibition of VV-HA-TNF replication
was not solely mediated by p55.
 
Both p55 and p75 TNFRs Contribute to the Attenuation of
VV-HA-TNF.
 
To determine the relative roles of p55 and
p75 in the attenuation of VV-HA-TNF, mice bearing mu-
tations in either or both TNFRs were infected with VV-
HA-TNF. The yields of virus recovered from TNFR-defi-
cient mice indicated that TNF bound both p55 and p75 to
initiate antiviral mechanisms (Fig. 1). Although the levels
of virus were undetectable in the ovaries of wild-type mice
3 d after infection with VV-HA-TNF, elevated replication
occurred in either p55- or p75-mutant mice (
 
P
 
 
 
,
 
0.001).
The contribution of both receptors to the attenuation of
VV-HA-TNF was confirmed by the increase in virus repli-
cation in mice deficient for both TNFRs compared to
wild-type mice (
 
P
 
 
 
,
 
0.01). Indeed, the attenuation of VV-
HA-TNF was completely abrogated in the double TNFR
 
2
 
/
 
2
 
mice, as the rVV replicated to the same extent as the con-
trol virus, VV-HA-TK (Table 1 and Fig. 1). There is no
evidence from these experiments to suggest that the antivi-
ral activity of TNF was mediated by mechanisms other than
 
Table 1.
 
Replication of rVV in p55
 
2
 
/
 
2
 
 Mice
 
Virus recovered (log
 
10
 
 PFU)
 
*
 
VV-HA-TNF VV-HA-TK
Wild type 1.8 
 
6
 
 0.1 6.9 
 
6
 
 0.0
p55
 
2
 
/
 
2
 
2.8 
 
6
 
 0.5
 
§
 
6.3 
 
6
 
 0.1
p55
 
2
 
/
 
2
 
 
 
1
 
 sTNFR
 
‡
 
4.2 
 
6
 
 0.4
 
i
 
ND
 
*
 
Mice were infected with 10
 
7
 
 PFU of rVV intravenously. Virus replica-
tion was assessed in the ovaries of mice 3 d after infection. Data shown
represent mean titers 
 
6
 
 SEM of virus present in total ovarian tissue of
5–10 individual mice. The limit of detection of the plaque-forming as-
say was 100 PFU and samples below this level were assigned a value of
50 (1.7 log
 
10
 
) PFU. Data are representative of three separate experi-
ments.
 
‡
 
Mice treated with sTNFR received 300 
 
m
 
g intraperitoneally on days
0, 1, and 2 after infection.
 
§
 
P
 
 
 
,
 
0.05, compared to wild-type mice infected with VV-HA-TNF,
Student’s 
 
t
 
 test.
 
i
 
P
 
 
 
,
 
0.05, compared to 55
 
2
 
/
 
2
 
 mice infected with VV-HA-TNF. 
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via p55 or p75. These data indicate that both p55 and p75
are necessary and sufficient to limit the replication of VV-
HA-TNF. In addition, the replication of VV-HA-TNF
was significantly greater in p75
 
2
 
/
 
2
 
 and p55
 
2
 
/
 
2
 
p75
 
2
 
/
 
2
 
 mice
compared to p55
 
2
 
/
 
2
 
 mice (
 
P
 
 
 
,
 
0.05; Fig. 1).
 
Impaired Antiviral Responses in p55
 
2
 
/
 
2
 
 and p75
 
2
 
/
 
2
 
 Mice.
 
As described above, the overexpression of TNF could af-
fect antiviral activity. Therefore, we sought evidence of a
role for TNF in the physiological control of virus infection.
Various strains of TNFR mutant mice were infected with
the natural murine pathogen EV. The mice used in these
studies were genetically resistant to EV; both C57BL and
129 backgrounds contribute to resistance to EV and B6 
 
3
 
129 mice were more resistant than either parent strain
(Ruby, J., unpublished data, and Karupiah, G., personal
communication). Consistent with the resistant phenotype,
no virus was detected in the livers of wild-type mice 7 d af-
ter infection (Fig. 2). In contrast, virus was demonstrated in
the livers of mice with mutations in either TNFR. The
level of EV recovered from the livers of p55
 
2
 
/
 
2
 
 mice was
consistently higher than that in wild-type mice, although
the difference was not statistically significant. However, sig-
nificantly higher yields of EV were obtained from the livers
of p75
 
2
 
/
 
2
 
 (
 
P
 
 
 
,
 
0.001) and p55
 
2
 
/
 
2
 
p75
 
2
 
/
 
2
 
 mice (
 
P
 
 
 
,
 
0.01)
relative to wild-type mice (Fig. 2). Furthermore, EV repli-
cated to a significantly greater extent in the livers of p75
 
2
 
/
 
2
 
mice compared to p55
 
2
 
/
 
2
 
 mice (
 
P
 
 
 
,
 
0.01; Fig. 2).
Increased levels of virus replication were also measured
in the spleens of TNFR mutant mice, compared to control
mice, 7 d after infection (Fig. 2). In this organ, significantly
higher EV titers were measured in p55
 
2
 
/2 (P ,0.05), p752/2
(P ,0.001), and p552/2p752/2 mice (P ,0.01) compared to
wild-type mice. Very high titers of virus were obtained
from the inoculated feet of all strains of mice, consistent
with the persistence of EV at this site (28, 29). However,
TNF did play a noticeable role in the control of virus repli-
cation at this site with significantly higher replication in
p552/2 mice (P ,0.05) and each of the p75-deficient
strains (P ,0.01; Fig. 2). Observations of morbidity of the
TNFR mutant mice reflected the yields of virus recovered.
The most dramatic effects were seen in p552/2 p752/2
mice which showed signs of severe morbidity (ruffled coat,
hunched appearance) 2 d after infection. At the time of
harvest, the popliteal lymph node draining the inoculation
site remained intact only in the control mice. Thus, defects
in either TNFR introduced susceptibility to EV.
To further test the antiviral role of the two TNFRs, sur-
vival of TNFR mutant mice infected with EV was moni-
tored. Wild-type mice recovered from infection with high
doses (5 3 103 PFU) of the virulent Moscow strain of EV.
Prominent swelling of the inoculated footpad was observed
in the wild-type mice. However, the footpad resumed a
normal appearance z14 d after infection. There were no
other visible signs of morbidity in these mice. In contrast,
clinical signs of susceptibility to EV, ranging from atrophy
of the infected foot to skin lesions and even mortality, were
seen in the TNFR mutant mice. Like the wild-type mice,
all p552/2 mice survived infection with EV (Fig. 3). How-
ever, the reduced resistance of these mice was indicated by
the symptoms of mousepox observed. Within 10 d of in-
fection, the inoculated foot of all p552/2 mice was severely
atrophied. Tail lesions were apparent in some (20%) mice
after 17 d, but these were resolved at the termination of the
experiment (42 d after infection). Mice lacking p75 were sig-
nificantly more susceptible to EV, with most (80%) mice
succumbing to lethal infection in the period from 10 to 21 d
Figure 1. Replication of VV-
HA-TNF in TNFR mutant
mice. Groups of five female mice
of the strains indicated were in-
fected intravenously with 107
PFU of VV-HA-TNF. The vi-
rus was recovered from the ova-
ries of mice 3 d after infection.
Data represent the mean titer 6
SEM for the total ovarian tissue
of five individual mice and are
representative of four separate
experiments. The limit of detec-
tion of the plaque-forming assay
was 100 PFU and samples below
this level were assigned a value of
50 (1.7 log10) PFU. **P ,0.01, compared to wild-type mice, Student’s t
test. ***P ,0.001, compared to wild-type mice.
Figure 2. Replication of EV
in TNFR2/2 mice. Groups of
five male mice of the strains indi-
cated were infected with 5 3 103
PFU of EV (Moscow) in the
right hind footpad. The mice
were killed 7 d after infection
and virus was assayed in the liver,
spleen, and inoculated foot. Data
are representative of the mean
virus titer 6 SEM of the tissues
shown for five individual mice.
For the liver, titers are expressed
per gram of tissue. Virus was re-
covered from the entire spleen
and foot. Morbidity of these
mice is discussed in the text.
Similar data were obtained in a
duplicate experiment in which
mice were infected with 104
PFU of EV (data not shown).
The limit of detection of the
plaque-forming assay was 100
PFU and samples below this
level were assigned a value of 50
(1.7 log10) PFU. *P ,0.05, in
comparison with wild-type mice,
Student’s t test. **P ,0.01, in
comparison with wild-type mice.
***P ,0.001, in comparison with
wild-type mice.1594 Tumor Necrosis Factor (TNF)R1 and TNFR2 Mediate Antiviral Activity
after infection (Fig. 3). Morbidity and mortality of p552/2
p752/2 mice was consistent with the increased susceptibil-
ity of p752/2 mice. EV infection was lethal for the majority
(60%) of p552/2p752/2 mice, which died between 10 and
17 d after infection (Fig. 3). Atrophy of the inoculated hind
foot was evident in all mice within 8 d of infection. At the
termination of the experiment, the surviving mice showed
generalized skin lesions.
Discussion
Using two different systems of virus infection of mice,
we have demonstrated that both p55 and p75 TNFR me-
diate the antiviral function of TNF in vivo. In an experi-
mental model, the overexpression of TNF during infection
with VV was previously shown to lead to rapid elimination
of the virus (5). This effect was partially dependent on p55
since the attenuation of VV was reversed to some extent in
p552/2 mice. However, a component of the antiviral mech-
anism was independent of p55 since treatment of these mice
with sTNFR caused further reversal of the attenuation. The
antiviral effects of TNF were totally inhibited in mice lack-
ing both TNFRs; in these mice VV-HA-TNF replicated to
the same extent as the control virus. Hence, both p55 and
p75 were required to activate TNF-dependent antiviral ac-
tivity. This conclusion was corroborated by studies of the
natural murine pathogen, EV, in TNFR2/2 mice. The ca-
pacity of TNFR mutant mice to resolve a normally self-
limiting infection was impaired. The increased replication
of EV in the target organs (liver and spleen) of p552/2 mice
and the clinical symptoms and morbidity consistent with
mousepox indicated that p55 plays a role in resistance to
this virus. However, the importance of p75 in the antiviral
response was highlighted by the increased susceptibility of
p552/2p752/2 mice; the lack of both TNFRs resulted in
high morbidity and mortality in otherwise resistant mice.
Together, these studies indicate that both TNFRs are nec-
essary and sufficient to mediate the antiviral effects of TNF.
Previously, a normal immune response to VV or LCMV
was reported (19) in the TNFR1/p552/2 mice used in this
study. We also found that the replication of the control VV
construct was not increased in p552/2 mice (Table 1). VV
exhibits only low virulence in mice, and lack of IFN-g or
IFN-a/b, or loss of function of CD8 T cells, is the only
factor shown to increase virulence of wild-type VV in re-
sistant mice (25, 27, 30, 31). Consistent with a less impor-
tant role for TNF in the host response to VV, the sTNFR
homologue is truncated in the VV genome (32). Based on
the data from this and other studies, it is possible to com-
pare the relative importance of antiviral cytokines. For in-
stance, while TNF clearly plays a determining role in resis-
tance to EV, it is less critical than IFN-g. When resistant
B6 mice were infected with a similar dose of EV, 100% of
mice treated with neutralizing anti–IFN-g antibodies died
within 7 d of infection (27). Although EV was lethal for
60–80% of mice deficient for both TNFRs, the survival
period was greatly extended, to z20 d.
The majority of TNF-dependent functions have been at-
tributed to signal transduction via TNFR1/p55 (17). In
contrast, a minor or accessory role has been proposed for
TNFR2/p75, with many studies supporting a ligand-pass-
ing role for p75 (19, 33, 34). In this scenario, p75 acts to
lower the effective concentration of TNF necessary to acti-
vate p55 by binding TNF and passing it to p75. However,
a distinct role for p75 in mediating cytotoxicity has been
suggested in addition to an accessory role (34). In particu-
lar, TNF-dependent activation-induced cell death of T cells
may be triggered by p75 (21, 35). The use of TNFR-spe-
cific antibodies has suggested that both receptors were re-
quired for the cutaneous inflammatory response after intra-
dermal injection of TNF (36) and that cytotoxicity was
greatly enhanced when both TNFRs were activated (37).
These cases suggest that cooperative signaling of TNFR may
occur independently of a ligand-passing mechanism. The for-
mation of p55/p75 heterocomplexes has been proposed as
an alternative mechanism to describe cooperative signaling
between TNFRs (38). In TNF-treated cells, TNFR-specific
mAb coprecipitated both p55 and p75. This finding sug-
gests a possible mechanism for the interaction of signaling
molecules downstream of either receptor.
A constant observation in mice infected with VV-HA-
TNF or EV was that the defect in the antiviral response of
p752/2 mice was greater than that of p552/2 mice. Al-
though it is well established that the soluble 17-kD form of
TNF binds p55 with higher affinity, it has recently been
proposed that the membrane-bound 26-kD TNF binds pre-
dominantly to p75 (39). It is possible that the dominant role
played by p75 in the antiviral studies we report reflects an
important role for membrane-bound TNF in activating an-
tiviral activity. In this regard, TNF expressed from cells in-
fected with VV-HA-TNF remained cell-associated 24 h after
infection and only reached maximal levels in the superna-
tant after 48 h (5), when lysis of the infected cells occurred.
Figure 3. Survival of TNFR2/2 mice infected with EV. Groups of five
male mice of various strains were infected with 5 3 103 PFU EV in a vol-
ume of 20 ml via the footpad. The strains of mice infected were C57BL/6
3 129 (wild-type control, e; p552/2, h; p752/2, s; and p552/2p752/2,
n). Similar observations were made in a duplicate experiment. Morbidity
is discussed in the text.1595 Ruby et al. Brief Definitive Report
This contrasts with maximal supernatant levels of secreted
cytokines, e.g., IL-2 from similar VV constructs within 12 h
of infection (24). Furthermore, the impaired response of
p552/2p752/2 mice to virus infection was not different from
that of p752/2 mice. Thus, there was no evidence of syner-
gistic or cooperative interaction between the two TNFRs
to support a ligand-passing role for p75 or a role for p55–
p75 complex formation in signaling antiviral activity. These
findings suggest that p75 plays an independent role in sig-
naling antiviral activity and that p75 appears to be more
important than p55 in the control of poxvirus infection. We
are currently attempting to address the question of whether
different antiviral mechanisms are mediated via each of the
TNFRs.
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